Clindamycin-rifampin combination therapy for staphylococcal periprosthetic joint infections: a retrospective observational study

Table 4 Failures

Case	Surgical treatment	Time from primary prosthesis to PJI (months)	Cultures	Antibiotic treatment	Time to recurrence of infection after ceasing AB (days)	Regimen	Cultures at reoperation
1	DAIR^a	49	S. aureus	Clinda^a/ rifampin 89 days	16	Suppressive clindamycin	-
2	DAIR	101	CoNS + S. mitis	Clinda / rifampin 41 days	28	Suppressive doxyclin	-
2	DAIR	101	CoNS + S. mitis	Levoflox^b / rifampin 86 days	28	Suppressive doxyclin	-
3	DAIR	1.5	S. aureus	Clinda / rifampin 19 days	0 (infection persisted)	Girdestone	Negative
3	DAIR	1.5	S. aureus	Fluclox^c / rifampin 6 days	0 (infection persisted)	Girdestone	Negative
4	DAIR	11	S. aureus	Clinda / rifampin 12 days	320	two stage revision	S. aureus
4	DAIR	11	S. aureus	Ciproxin^d / rifampin 83 days	320	two stage revision	S. aureus
5	Revision	48	S. capitis	Clinda / rifampin 92 days	0	Girdlestone	S. capitis

PJI prosthetic joint infection; AB antibiotics; DAIR debridement and implant retention; CoNS coagulase negative Staphylococci
^aClindamycin
^bLevofloxacin
^cFlucloxacillin
^dCiprofloxacin

ISSN: 1471-2334